Optimizing Structure and Impact of the Market Access Function

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Meeting the Needs of Payers Through the Market Access Function: Structure, Impact, and Activities”

STUDY OVERVIEW

The Market Access function has steadily attained importance due to the increased need for value over existing treatments among regulatory and reimbursement agencies. Recognizing this, pharmaceutical companies are establishing dedicated Market Access teams with well-defined roles and responsibilities.

Best Practices, LLC conducted benchmarking research to uncover winning practices that enhance operational performance and improve payer engagement. This study focuses on pivotal aspects, including leadership dynamics, structural innovations, reporting relationships, critical activities, and engagement metrics.

KEY TOPICS

Market Access Leadership Dynamics
Market Access Structure and Reporting
Effective Payer Engagement Activities
Operational Impact of Market Access Function

KEY METRICS

Leadership goals for Market Access teams
Existing and preferred Market Access function structures
Functions to which Market Access groups typically report
Leadership reporting levels for Market Access
Market Access function's influence on listed operational categories
Assessing payer engagement activities and their impact on Market Access organization success
Effectiveness of payer engagement metrics

SAMPLE KEY FINDINGS

Activities and Impact Insights: Relationship management and insight gathering from payers are universally acknowledged as effective strategies to enhance success in Market Access.

METHODOLOGY

Best Practices, LLC engaged 11 Market Access leaders across diverse biopharma organizations in this benchmarking research.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Market Research

Companies Profiled:
AbbVie; Alkermes; Bayer; Boehringer Ingelheim; F2G - The Rare Fungal Disease Company; Ferring Pharmaceuticals; Health Industries Research Companies (HIRC); Idorsia; Ipsen; Jazz Pharmaceuticals; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Meeting the Needs of Payers Through the Market Access Function: Structure, Impact, and Activities

ID: 5789

Features:

Pages/Slides: 20

Published: 2024

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E91E294081B2040800258AA9002888C8
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-meeting-needs-of-payers-through-market-access-function-structure-impact-activities?opendocument
18
19opendocument
2018.97.9.172
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB